Back to Clinical Trials Overview

Back To Cancer Clinical Trials

Your search for "Skin" returned 8 results:


Phase II Trial of Nab-Paclitaxel as First Line cytotoxic Chemotherapy in Patients with Unresectable Cutaneous Squamous Cell Carcinoma
Principal Investigator(s): Philip Friedlander

In Situ, Autologous Therapeutic Vaccination Against Solid Cancers with Intratumoral Hiltonol® (Poly-ICLC)
Principal Investigator(s): Nina Bhardwaj

A Multi-center, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence
Principal Investigator(s): Yvonne Saenger

In Situ, Autologous Therapeutic Vaccination Against Solid Cancers with Intratumoral Hiltonol® (Poly-ICLC)
Principal Investigator(s): Nina Bhardwaj

A Phase 1 Dose-Escalation Study of LY2940680 in Patients with Advanced Cancer
Principal Investigator(s): Philip Friedlander

The Effect of BRAF Inhibition with Vemurafenib on the Innate and Adaptive Immune Systems in Patients with Unresectable Stage III or Stage IV Melanoma Expressing a V600 BRAF Mutation
Principal Investigator(s): Philip Friedlander

A Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab Compared to Ipilimumab Alone in Subjects With Previously Untreated, Unresectable, Stage IIIb-IV Melanoma
Principal Investigator(s): Yvonne Saenger

An Extension Protocol to Evaluate the Efficacy and Safety of Extended Use Treatment with OncoVEXGM-CSF for Eligible Patients Participating In Study 005/05
Principal Investigator(s): Yvonne Saenger